Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.

Author
:
RJ Landovitz
D Donnell
ME Clement
B Hanscom
L Cottle
L Coelho
R Cabello
S Chariyalertsak
EF Dunne
I Frank
JA Gallardo-Cartagena
AH Gaur
P Gonzales
HV Tran
JC Hinojosa
EG Kallas
CF Kelley
MH Losso
JV Madruga
K Middelkoop
N Phanuphak
B Santos
O Sued
Valencia Huamaní
ET Overton
S Swaminathan
C Del Rio
RM Gulick
P Richardson
P Sullivan
E Piwowar-Manning
M Marzinke
C Hendrix
M Li
Z Wang
J Marrazzo
E Daar
A Asmelash
TT Brown
P Anderson
SH Eshleman
M Bryan
C Blanchette
J Lucas
C Psaros
S Safren
J Sugarman
H Scott
JJ Eron
SD Fields
ND Sista
K Gomez-Feliciano
A Jennings
RM Kofron
TH Holtz
K Shin
JF Rooney
KY Smith
W Spreen
D Margolis
A Rinehart
A Adeyeye
MS Cohen
M McCauley
B Grinsztejn
Team. Study
Abstract
:

Safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preventing HIV infection.
Year of Publication
:
2021
Journal
:
The New England journal of medicine
Volume
:
385
Issue
:
7
Number of Pages
:
595-608
Date Published
:
2021
ISSN Number
:
0028-4793
URL
:
https://www.nejm.org/doi/10.1056/NEJMoa2101016?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
DOI
:
10.1056/NEJMoa2101016
Short Title
:
N Engl J Med
Download citation